Board MeetingApr 10, 2026, 04:04 PM
Allogene to Host Call on Phase 2 ALPHA3 Trial Futility Analysis
AI Summary
Allogene Therapeutics, Inc. announced it will host a conference call and webcast on Monday, April 13, 2026, at 8:30 a.m. ET. The purpose of the call is to review the interim futility analysis from its pivotal, randomized Phase 2 ALPHA3 trial. This trial is evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma (LBCL).
Key Highlights
- Allogene to host conference call on April 13, 2026.
- Call to review interim futility analysis of Phase 2 ALPHA3 trial.
- Trial evaluates cema-cel in first-line LBCL.